OlwenMHahnMD

Oncology • Chicago, IL

Breast Cancer, Genitourinary Oncology, Hematologic Oncology

Associate Professor, University of Chicago

Join to view full profile

Dr. Hahn is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hahn's full profile

Already have an account?

Office
5841 S. MARYLAND
M/C 2115
Chicago, IL 60637
Phone+1 773-702-5381

Fax+1 773-702-3163

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 2004 - 2007
University of ChicagoResidency, Internal Medicine, 2001 - 2004
Emory University School of MedicineClass of 2001

Certifications & Licensure

IL State Medical License 2001 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery Start of enrollment: 2013 Dec 13
Active, not recruiting
Phase 3
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Start of enrollment: 2014 Mar 29
Active, not recruiting
Phase 3
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer Start of enrollment: 2015 May 28
Active, not recruiting
Phase 2
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases Start of enrollment: 2016 Sep 15
Active, not recruiting
Phase 2
Breast Cancer WEight Loss Study (BWEL Study) Start of enrollment: 2016 Aug 01
Active, not recruiting
Phase 3
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy Start of enrollment: 2016 Dec 08
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

3 citations
Validation of the RSClin risk calculator in the National Cancer Data Base.
Augustin G L Vannier, Asim Dhungana, Fangyuan Zhao, Nan Chen, Sarah Shubeck
Cancer. 2024-04-15
71 citations
Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positi...
Aranzazu Fernandez-Martinez, Ian E. Krop, David W. Hillman, Mei Yin C. Polley, Joel S. Parker
Journal of Clinical Oncology. 2020-10-23
235 citations
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progress...
Toni K. Choueiri, Colin Hessel, Susan Halabi, Ben L. Sanford, M. Dror Michaelson
European Journal of Cancer. 2018-03-20

Journal Articles

Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised ...
Toni K Choueiri, Olwen Hahn, Thomas Olencki, Eric J Small, Shaker Dakhil, Darren R Feldman, European Journal of Cancer

Authored Content

Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival Update’ [Eur J Cancer 94 (May 2018) 115–125]September 2018
Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival UpdateApril 2018

Press Mentions

Bodybuilder’s Battle with Breast Cancer: “Emotionally I Was a Wreck.”January 27th, 2022

Professional Memberships

American Society of Clinical Oncology - ASCO
Member